The dysmenorrhea treatment market was valued at USD 7.2 billion in 2025, is projected to reach USD 15.2 billion by 2036 and is forecast to register a 7.1% CAGR between 2026 and 2036. In 2026, non-steroidal anti-inflammatory drugs (NSAIDs) hold 43.0% of treatment type demand and primary dysmenorrhea represents 76.0% of dysmenorrhea type sales.